This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay D treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
BrainsWay® CMO, Dr. Aron Tendler, was interviewed by Corebrain Journal about Deep TMS and its usage an treatment for depression and other conditions.
[Deep] TMS provides some surprisingly fresh answers to previously “untreatable” psychiatric problems.This is how our interview with Dr Tendler started: he hit fresh interventions strategies hard – right out of the box – and continued with deep insights throughout our too-brief conversation. Note: He agreed to return now that we’ve had this opportunity for an introduction on this exceedingly interesting technology and treatment. dTMS does appear to provide significant answers for refractory responses on many levels – see this list of Indications that are currently under investigation – they’re more than just “interesting.”
Read more about the interview, and listen to the podcast here.